According to preliminary figures, Plan Optik AG’s consolidated sales increased by EUR 1,787 thousand in the 2023 financial year from EUR 11,466 thousand to EUR 13,253 thousand. Consolidated sales had already increased by EUR 1,999 thousand in 2022. The strong growth in 2023 is largely due to successful medical and pharmaceutical products in the microfluidics business segment. In addition, the positive development in the carrier wafer business segment contributed significantly to the growth in sales. Carrier wafers are used for production in the semiconductor industry.

According to preliminary figures, the Group’s EBITDA rose to EUR 3,075 thousand in the 2023 financial year, compared to EUR 2,748 thousand in the previous year. The EBITDA margin was therefore 23%. EBIT rose from EUR 2,040 thousand to EUR 2,320 thousand and EBT from EUR 1,981 thousand to EUR 2,298 thousand.

While the Executive Board expects this successful development to continue from 2025 onwards, a significant temporary decline in Group sales and earnings is expected for the current 2024 financial year. Several customers have announced plans to reduce their inventories. From today’s perspective, this will lead to one-off shifts in sales. Inventories are currently being reduced across all sectors now that material supplies have become more secure again worldwide.

From 2025 onwards, the Executive Board expects the Group’s sales and profits to increase significantly again once customer inventories have been cleared and a return to the previously planned growth path. This is because, at the same time as existing customers are expected to return to their usual orders, additional customers are likely to start series production based on microstructured elements and components from Plan Optik.

In order to be able to meet the demand forecast for the coming years, production capacities are currently being expanded across the Group. In this context, the production areas at the Hungarian site have also recently been significantly expanded.